Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial

Table 2 Blood loss during the postoperative period

Variable	Group A (n = 60)	Group B (n = 60)	Group C (n = 60)	Pairwise Comparison (P value)			P Value
Variable	Group A (n = 60)	Group B (n = 60)	Group C (n = 60)	Group A vs B	Group A vs C	Group B vs C	P Value
Intraoperative blood loss	78.3 ± 22.4	84.6 ± 29.1	80.3 ± 23.9	0.3621	0.9019	0.6215	0.3805
Blood loss till postoperative day 1	284.8 ± 112.9	371.2 ± 124.6	522.4 ± 189.4	< 0.01^a	< 0.001^a	< 0.001^a	< 0.001^a
Total blood loss	514.5 ± 204.6	642.6 ± 232.9	881.6 ± 314.9	0.0179^a	< 0.001^a	< 0.001^a	< 0.001^a

The p value represents the result of one-way analysis of variance for independent means for continuous variables
^ameans significant difference

ISSN: 1471-2474